Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102966 · ClinicalTrials.gov registry record · NA
Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas
A NA study of Rare Diseases, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 410
- Enrollment target
- 1
- Study location
NCT07102966: Recruiting NA study of Rare Diseases, sponsored by Baylor College of Medicine.
NCT07102966 is a NA study of Rare Diseases that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 410 participants, below the 17,417-participant average among 7 other Rare Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07102966, a NA study of Rare Diseases, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 410 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to provide advanced genetic testing and virtual consultations for seriously ill newborns in hospitals in Texas with fewer resources, especially along the Texas-Mexico border. The researchers also want to know how well the virtual consultation tool, called Consultagene, works in these hospitals by gathering feedback from healthcare providers. Researchers will provide rapid whole genome sequencing (WGS) to 200 infants over a period of 5 years. Data will be collected via Consultagene, surveys, and qualitative interviews.
Primary Outcome
The primary outcome will be effectiveness of Consultagene, defined as difference in diagnostic yield compared to usual care.
Conditions Studied
Interventions
- GENETIC Rapid whole genome sequencing
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2029-07-31 |
| Phase | NA |
What NCT07102966 shows while recruiting
NCT07102966 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, below the 17,417-participant average among 7 other Rare Diseases trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Rare Diseases appearing as the primary indexed condition, and to 1 intervention - of which Rapid whole genome sequencing is the first listed.
NCT07102966 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07102966 about?
NCT07102966 is a clinical study titled "Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas". The purpose of this study is to provide advanced genetic testing and virtual consultations for seriously ill newborns in hospitals in Texas with fewer resources, especially along the Texas-Mexico border. The researchers also want to know how well the virtual consultation tool, called Consultagene, w...
What is the current status of trial NCT07102966?
This trial is currently recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2025-10-28. Estimated completion is 2029-07-31.
What conditions does trial NCT07102966 study?
This clinical trial studies the following conditions: Rare Diseases.
What interventions are being tested in trial NCT07102966?
The interventions under investigation include: Rapid whole genome sequencing (GENETIC).
Who is sponsoring clinical trial NCT07102966?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07102966 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rare Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants
COMPLETED · NA
-
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
RECRUITING · Phase 2
-
Longitudinal Studies of Patient With FPDMM
RECRUITING
-
Baker Gordon Syndrome Natural History Study
RECRUITING
-
UW Undiagnosed Genetic Diseases Program
RECRUITING
-
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI